Bulgaria’s Biovet 9-mo cons net profit up 35% Bulgarian veterinary drugs producer Biovet said on Tuesday its consolidated net profit rose by 35.4% on the year to 8.4 million levs for first nine months of 2013. Net earnings per share rose to 1.24 levs in the period from 0.91 levs in the first nine months of 2012, the company said in a statement filed with the Sofia stoch exchange. Biovet’s sales revenue increased to 133.9 million levs in the January-September period from 128 million levs a year earlier. Biovet is 82.36 % owned by Bulgarian pharmaceutical company Huvepharma, backed by Citi Venture Capital International (CVCI).
Source: Capital (13.11.2013)